Tapestry, Inc. vs Twist Bioscience Corp — how do they compare? Tapestry, Inc. trades at $113.97 (market cap $23.44B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Tapestry, Inc. is far larger — about 2.8× Twist Bioscience Corp's market cap, and Tapestry, Inc. pays a 1.57% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TPR | TWST | |
|---|---|---|
Market Cap | $23.44B | $8.42B |
Sector | Consumer Cyclical | Health |
52-Week High | $164.78 | $153.10 |
52-Week Low | $98.81 | $24.16 |
Enterprise Value | $26.25B | $8.35B |
Dividend Yield | 1.57% | — |
Signals from Pluang's Aura AI — not financial advice
TPR (Tapestry Inc.) is trading at $117.58, down 3.73% in the last session, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined significantly. Recent earnings have consistently beaten estimates, and analyst consensus remains strongly bullish with a $182.44 price target representing 55% upside potential.
The outlook remains positive with international growth accelerating in China and Europe, supported by a direct-to-consumer model. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation. Institutional buying activity remains strong, with BlackRock acquiring a $2.6 billion position in Q2 2026, supporting the bullish analyst sentiment.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Trailing returns across standard periods
Latest headlines on both assets
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →